The Vercoulen lab publishes new findings which can help predict melanoma patient response to anti-PD-1 treatment

The authors find that monocyte-derived macrophages (MDMs) and cytotoxic T-cells in the tumor microenvironment can help predict who will benefit from anti–PD-1 treatment. This suggests that MDM infiltration could be a new biomarker to guide personalized immunotherapy and improve survival outcomes. Read more: https://www.nature.com/articles/s41416-025-03137-8